You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
DBL Docetaxel Concentrated Injection is indicated for:,Breast cancer,Metastatic breast cancer
Treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed.
DBL Docetaxel Concentrated Injection in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.
DBL Docetaxel Concentrated Injection in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.
Adjuvant treatment of breast cancer
DBL Docetaxel Concentrated Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node positive breast cancer.
Doxorubicin and cyclophosphamide followed by DBL Docetaxel Concentrated Injection in combination with trastuzumab (AC-TH) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress HER2.
DBL Docetaxel Concentrated Injection in combination with carboplatin and trastuzumab (TCH) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress HER2.
DBL Docetaxel Concentrated Injection in combination with cyclophosphamide is indicated for the adjuvant treatment of operable breast cancer with a primary tumour of = 1cm and < 7cm.,Non-small cell lung cancer
Treatment of patients with locally advanced or metastatic non-small cell lung cancer, including those who have failed platinum-based chemotherapy.,Ovarian cancer
Treatment of metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapy.,Prostate cancer
Treatment of patients with androgen independent (hormone refractory) prostate cancer.,Head and neck cancer
DBL Docetaxel Concentrated Injection in combination with cisplatin and fluorouracil (TPF), is indicated as induction treatment prior to chemoradiotherapy, for the treatment of patients with locally advanced, squamous cell carcinoma of the head and neck, who have low probability of surgical cure, require organ preservation or where the tumour is technically unresectable.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on January, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
DBL Docetaxel Concentrated Injection is indicated for:,Breast cancer,Metastatic breast cancer
Treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed.
DBL Docetaxel Concentrated Injection in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.
DBL Docetaxel Concentrated Injection in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.
Adjuvant treatment of breast cancer
DBL Docetaxel Concentrated Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node positive breast cancer.
Doxorubicin and cyclophosphamide followed by DBL Docetaxel Concentrated Injection in combination with trastuzumab (AC-TH) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress HER2.
DBL Docetaxel Concentrated Injection in combination with carboplatin and trastuzumab (TCH) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress HER2.
DBL Docetaxel Concentrated Injection in combination with cyclophosphamide is indicated for the adjuvant treatment of operable breast cancer with a primary tumour of = 1cm and < 7cm.,Non-small cell lung cancer
Treatment of patients with locally advanced or metastatic non-small cell lung cancer, including those who have failed platinum-based chemotherapy.,Ovarian cancer
Treatment of metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapy.,Prostate cancer
Treatment of patients with androgen independent (hormone refractory) prostate cancer.,Head and neck cancer
DBL Docetaxel Concentrated Injection in combination with cisplatin and fluorouracil (TPF), is indicated as induction treatment prior to chemoradiotherapy, for the treatment of patients with locally advanced, squamous cell carcinoma of the head and neck, who have low probability of surgical cure, require organ preservation or where the tumour is technically unresectable.
DBL Docetaxel Concentrated Injection is indicated for:,Breast cancer,Metastatic breast cancer
Treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed.
DBL Docetaxel Concentrated Injection in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.
DBL Docetaxel Concentrated Injection in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.
Adjuvant treatment of breast cancer
DBL Docetaxel Concentrated Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node positive breast cancer.
Doxorubicin and cyclophosphamide followed by DBL Docetaxel Concentrated Injection in combination with trastuzumab (AC-TH) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress HER2.
DBL Docetaxel Concentrated Injection in combination with carboplatin and trastuzumab (TCH) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress HER2.
DBL Docetaxel Concentrated Injection in combination with cyclophosphamide is indicated for the adjuvant treatment of operable breast cancer with a primary tumour of = 1cm and < 7cm.,Non-small cell lung cancer
Treatment of patients with locally advanced or metastatic non-small cell lung cancer, including those who have failed platinum-based chemotherapy.,Ovarian cancer
Treatment of metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapy.,Prostate cancer
Treatment of patients with androgen independent (hormone refractory) prostate cancer.,Head and neck cancer
DBL Docetaxel Concentrated Injection in combination with cisplatin and fluorouracil (TPF), is indicated as induction treatment prior to chemoradiotherapy, for the treatment of patients with locally advanced, squamous cell carcinoma of the head and neck, who have low probability of surgical cure, require organ preservation or where the tumour is technically unresectable.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on January, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
